Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases

Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.